This study is designed to test whether BHV-2100 is safe and effective in reducing headache pain and other symptoms in the treatment of migraine. BHV-2100 is a new type of drug taken by mouth that blocks a specific receptor called TRPM3, which is involved in signaling pain. If you qualify, you will take a single tablet of BHV-2100 or a matching placebo.
You may qualify for this study if you:
- Are between 18-64 years old
- Have at least 1 year history of migraine (with or without aura) including onset before age 50
- Have 2-8 migraine attacks of moderate or severe intensity in each of the 3 months prior to the screening visit
-
Less than 15 days with headaches (migraine or non-migraine) per month
For more information about the BHV-2100 study, and to see if you may qualify, please email ResearchNCNE@myneurodr.com / call 781-551-5812 opt.2.